HUTCHMED DRC (HCM) earnings

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $2.3B

In the quarter ended December 2019, HUTCHMED DRC had revenue of $53M, up 0.4% on a year earlier.

Quarterly results

The last 8 quarters from HUTCHMED DRC's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Dec 31, 2019$53M +0.4% — — -72.0% 2020-03-03
Sep 30, 2019$49M -16.1% — — -72.8% 2020-01-21
Jun 30, 2019$50M +0.4% — — -71.9% 2019-07-30
Mar 31, 2019$52M -0.3% -0.03 — -69.1% 2019-06-06
Dec 31, 2018$53M — — — -45.5% 2019-03-11
Sep 30, 2018$59M — — — -25.1% 2020-01-21
Jun 30, 2018$50M — — — -57.5% 2018-07-27
Mar 31, 2018$52M — -0.02 — -47.8% 2019-06-06
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for HCM.
Open HCM in Investingly

Questions

How did HUTCHMED DRC do last quarter?

In the quarter ended December 2019, HUTCHMED DRC had revenue of $53M, up 0.4% on a year earlier.

From HUTCHMED DRC's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.